Eventide Asset Management’s Seres Therapeutics MCRB Stock Holding History

Eventide Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,910	Closed	-$2.19M	–	130
2016 Q3	$2.19M	Hold	8,910	–	–	0.13%	95
2016 Q2	$5.18M	Hold	8,910	–	–	0.32%	72
2016 Q1	$4.73M	Hold	8,910	–	–	0.26%	77
2015 Q4	$6.25M	Buy	8,910 +3,533	+66%	+$2.32M	0.31%	77
2015 Q3	$3.19M	Buy	+5,377	New	+$4.39M	0.19%	89

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Eventide Asset Management's MCRB Position: Q4 2016 in Review

Eventide Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2016, closing a stake of 8,910 shares — an estimated $2.19M sold.

Eventide Asset Management first reported a position in MCRB in Q3 2015 and held it in 5 quarters. The position peaked at $6.25M in Q4 2015. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

Eventide Asset Management reported no remaining Seres Therapeutics position as of Q4 2016 after selling out during the quarter.
Eventide Asset Management sold 8,910 Seres Therapeutics shares in Q4 2016, an estimated $2.19M.
Eventide Asset Management first reported a position in Seres Therapeutics in Q3 2015 and held it in 5 quarters.
Eventide Asset Management's Seres Therapeutics position peaked at $6.25M in Q4 2015.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on Eventide Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.